Therefore, although the vulnerability to ICP0-null HSV-1 was found through testing a hypothesis regarding ATRX-deficient ALT cancer cells, the additional findings regarding PML may have uncovered a target for selective oncolytic viral therapy in a wider array of tumor types, namely, low PML levels, regardless of the cause of the downregulation. The gene discussed is ATRX; the disease is cancer.